Get all premium features to the best stock analysis tool

Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%

Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the procurement of NexoBrid®, establishment and maintenance of a Vendor Managed Inventory (VMI) system, design and validation of a U.S based manufacturing facility, and the development of a next generation formulation and additional indication for NexoBrid.

Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results

Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin of 79% and Adjusted EBITDA Margin of 40% Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025.

Vericel Announces Preliminary 2025 Financial Results and Business Updates

Total Revenue Expected to be $276 Million  MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results and other business updates for the fourth quarter and year ended December 31, 2025.